Synapse - Works

Results (2146)

Longer-term safety and efficacy of selinexor maintenance therapy for patients with TP53WT advanced or recurrent endometrial cancer: Follow up subgroup analysis of the ENGOT-EN5/GOG-3055/SIENDO study

Meeting Abstract

Fidalgo, J. A. P.; Vergote, I.; Hamilton, E.; Giorgi, U. D.; Gorp, T. V.; Lübbe, K.; Zikan, M.; Helpman, L.; Miller, D. S.; Fariñas-Madrid, L.; more...
International Journal of Gynecological Cancer (2024)

Fulltext@MSK | Save

Benefit from atezolizumab in patients with a poor prognostic ovarian cancer in first-line setting: IMAGYN-050 trial

Meeting Abstract

You, B.; Anderson, C.; Cecere, S. C.; Carrot, A.; Myers, T.; Heitz, F.; Sudarshan, S.; Selcukbiricik, F.; Aghajanian, C.; Fernebro, J.; more...
International Journal of Gynecological Cancer (2024)

Fulltext@MSK | Save

A phase 3, randomized trial evaluating avutometinib plus defactinib compared with investigator’s choice of therapy in patients with recurrent low-grade serous ovarian cancer: GOG-3097/ENGOT-ov81/NCRI/RAMP 301

Meeting Abstract

Grisham, R.; Monk, B.; Van Nieuwenhuysen, E.; Moore, K.; Fabbro, M.; O'Malley, D.; Oaknin, A.; Thaker, P.; Oza, A.; Colombo, N.; more...
International Journal of Gynecological Cancer (2024)

Fulltext@MSK | Save

Randomized, phase II/III study of pegylated liposomal doxorubicin, bevacizumab, and atezolizumab in platinum-resistant ovarian cancer (NRG-GY009): Clinical outcomes by PD-L1 and T cell infiltration status

Meeting Abstract

O'Cearbhaill, R.; Zamarin, D.; Sill, M.; Duong, H.; Waggoner, S.; Grisham, R.; Backes, F.; Mannel, R.; Tanyi, J.; Powell, M.; more...
International Journal of Gynecological Cancer (2024)

Fulltext@MSK | Save

Efficacy and safety of avutometinib ± defactinib in recurrent low grade serous ovarian cancer: Primary analysis of ENGOT-OV60/GOG-3052/RAMP 201

Meeting Abstract

Banerjee, S.; Aghajanian, C.; Van Nieuwenhuysen, E.; Santin, A.; Ring, K.; Colombo, N.; Thaker, P.; Prendergast, E.; Moore, K.; Chon, H. S.; more...
International Journal of Gynecological Cancer (2024)

Fulltext@MSK | Save

First-in-human (FIH) phase I data of HST-1011, an oral CBL-B inhibitor, in patients with advanced solid tumors

Meeting Abstract

Sanborn, R. E.; Patel, M. R.; Rodon, J.; Thein, K. Z.; Friedman, C.; Levitz, D.; Ngirailemesang, I.; Goodman, A.; Agarwal, P.; Friedman, E.; more...
Annals of Oncology (2024)

Fulltext@MSK | Save

A first-in-human phase I study of LY4170156, an antibody-drug conjugate targeting folate receptor α (FRα)-expressing advanced solid tumors

Meeting Abstract

Ray-Coquard, I. L.; Liu, J. F.; O'Malley, D.; Oaknin, A.; Pothuri, B.; Lorusso, D.; Eskander, R. N.; Westin, S.; Lakhani, N. J.; McKean, W. B.; more...
Annals of Oncology (2024)

Fulltext@MSK | Save

Safety and tolerability of durvalumab (D) + carboplatin/paclitaxel (CP) + bevacizumab (B) followed by D, B + olaparib (O) maintenance (mtx) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) without a tumour BRCA1/BRCA2 mutation (non-tBRCAm) in the phase III DUO-O trial

Meeting Abstract

Aghajanian, C.; Schmalfeldt, B.; Okamoto, A.; Reuss, A.; Kim, J. W.; Marquina Ospina, G.; Ayhan, A.; Salutari, V.; Lebreton, C.; Labudovic, D.; more...
Annals of Oncology (2024)

Fulltext@MSK | Save

A phase II study of ACR-368 in patients with ovarian (OvCa) or endometrial carcinoma (EnCa) and prospective validation of OncoSignature patient selection (NCT05548296)

Meeting Abstract

Lee, J. M.; MacLaughlan, S.; Matei, D.; Song, M.; Brubaker, L.; Rimmel, B.; Eskander, R. N.; Kyi, C.; Williams, H.; Duska, L.; more...
Annals of Oncology (2024)

Fulltext@MSK | Save

Phase I safety and efficacy of brenetafusp, a PRAME x CD3 ImmTAC T cell engager, in platinum resistant ovarian cancer (PROC)

Meeting Abstract

Friedman, C.; De Burgh Williams, A.; Lopez, J. S.; Ouali, K.; Middleton, M. R.; Thistlethwaite, F.; Hamid, O.; Izar, B.; Moreno Garcia, V.; Johnson, M. L.; more...
Annals of Oncology (2024)

Fulltext@MSK | Save